| Accession |
PRJCA012446 |
| Title |
Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+ /HER2- Breast Cancer |
| Relevance |
Medical |
| Data types |
Genome sequencing and assembly
|
| Organisms |
Homo sapiens
|
| Description |
It is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy with/without a CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria. |
| Sample scope |
Multiisolate |
| Release date |
2022-10-12 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Binghe
Xu (xubinghe@csco.org.cn)
|
| Organization |
Cancer Hospital, Chinese Academy of Medical Sciences |
| Submission date |
2022-10-12 |
